Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of rezafungin, the company’s Phase 3 antifungal, and CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza, will be presented at the American Society for Microbiology (ASM) Microbe 2019 annual meeting taking place June 20-24 in San Francisco. “Our presentations at ASM Microbe underscore our ongoing commitment to developing new anti-infectives to address the urgent need for innovation in this space,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We are excited to present new data that further reinforce the potential of rezafungin to address a range of serious, life-threatening fungal infections, including azole-resistant invasive aspergillosis, as well as new data highlighting CB-012’s unique mechanism of action and novel approach to engage the immune system to treat and prevent seasonal and pandemic flu.”
|
Thread abonnieren
